UKRMP First Annual Report now available.
The Report details the key components of the £25M UK Regenerative Medicine Platform (UKRMP) established by BBSRC, EPSRC and the MRC.
The UKRMP will address the technical and scientific challenges associated with translating promising scientific discoveries in this area towards clinical impact, and seeks to provide a world-leading programme to promote the development of regenerative therapies. Central to the Platform are five interdisciplinary and complementary research Hubs with the necessary critical mass to address key translational challenges and provide new tools, protocols and resources with broad applicability that can be utilized by other UK research groups in academia and industry.
Theme 5: Immunomodulation Hub
In addition, the PIs from each of the five Disease/Systems focused UKRMP awards describe their research programmes, which are:
Professor Charles Archer, Swansea University.
Repair of cartilage defects using tissue-specific adult stem cells
Professor Pete Coffey, University College London.
iPSC-based cellular replacement therapy of the dry form of age-related macular degeneration
Dr David Hay, MRC Centre for Regenerative Medicine, University of Edinburgh
The development of 3-dimensional implantable liver organoids
Professor Andrew McCaskie, University of Cambridge
Stepwise translational pathway for smart material cell therapy for osteoarthritis
Professor Manuel Salmeron-Sanchez, University of Glasgow.
Synergistic microenvironments for non-union bone defects
Finally, the strategic central role of the UKRMP in relation to the UK’s regen med landscape is presented.
Click on the link to view a copy of the UKRMP First Annual Report (2.0MB)
Thursday, November 20, 2014
The database, which is launched today, has identified over 100 sources of funding from 34 organisations, totalling over £3bn for […]More »
Friday, November 7, 2014
The Report details the key components of the £25M UKRMP established by BBSRC, EPSRC and the MRC. Within the Report […]More »
Monday, October 13, 2014
The MHRA and HTA have announced a new ‘One stop shop’ regulatory advice service for regenerative medicine. This follows as […]More »